Climb Bio reports Phase 1 data for anti-APRIL antibody CLYM116 in IgA nephropathy program
The company said a single 320 mg dose drove near-complete APRIL suppression and 60-75% IgA and Gd-IgA1 reduction through 12 weeks, supporting a possible every-12-week dosing schedule.
SEC filing